BACKGROUND: The Overall Anxiety Severity and Impairment Scale (OASIS) is a 5-item self-report measure that can be used to assess severity and impairment associated with any anxiety disorder or multiple anxiety disorders. A prior investigation with a nonclinical sample supported the reliability and validity of the OASIS; however, to date it has not been validated for use in clinical samples. METHODS: The present study assessed the psychometric properties of the OASIS in a large sample (N=1036) of primary care patients whose physicians referred them to an anxiety disorders treatment study. Latent structure, internal consistency, convergent/discriminant validity, and cut-score analyses were conducted. RESULTS: Exploratory and confirmatory factor analyses supported a unidimensional structure. The five OASIS items displayed strong loadings on the single factor and had a high degree of internal consistency. OASIS scores demonstrated robust correlations with global and disorder-specific measures of anxiety, and weak correlations with measures of unrelated constructs. A cut-score of 8 correctly classified 87% of this sample as having an anxiety diagnosis or not. LIMITATIONS: Convergent validity measures consisted solely of other self-report measures of anxiety. Future studies should evaluate the convergence of OASIS scores with clinician-rated and behavioral measures of anxiety severity. CONCLUSIONS: Overall, this investigation suggests that the OASIS is a valid instrument for measurement of anxiety severity and impairment in clinical samples. Its brevity and applicability to a wide range of anxiety disorders enhance its utility as a screening and assessment tool.
BACKGROUND: The Overall Anxiety Severity and Impairment Scale (OASIS) is a 5-item self-report measure that can be used to assess severity and impairment associated with any anxiety disorder or multiple anxiety disorders. A prior investigation with a nonclinical sample supported the reliability and validity of the OASIS; however, to date it has not been validated for use in clinical samples. METHODS: The present study assessed the psychometric properties of the OASIS in a large sample (N=1036) of primary care patients whose physicians referred them to an anxiety disorders treatment study. Latent structure, internal consistency, convergent/discriminant validity, and cut-score analyses were conducted. RESULTS: Exploratory and confirmatory factor analyses supported a unidimensional structure. The five OASIS items displayed strong loadings on the single factor and had a high degree of internal consistency. OASIS scores demonstrated robust correlations with global and disorder-specific measures of anxiety, and weak correlations with measures of unrelated constructs. A cut-score of 8 correctly classified 87% of this sample as having an anxiety diagnosis or not. LIMITATIONS: Convergent validity measures consisted solely of other self-report measures of anxiety. Future studies should evaluate the convergence of OASIS scores with clinician-rated and behavioral measures of anxiety severity. CONCLUSIONS: Overall, this investigation suggests that the OASIS is a valid instrument for measurement of anxiety severity and impairment in clinical samples. Its brevity and applicability to a wide range of anxiety disorders enhance its utility as a screening and assessment tool.
Authors: Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Patrick O Monahan; Bernd Löwe Journal: Ann Intern Med Date: 2007-03-06 Impact factor: 25.391
Authors: Greer Sullivan; Michelle G Craske; Cathy Sherbourne; Mark J Edlund; Raphael D Rose; Daniela Golinelli; Denise A Chavira; Alexander Bystritsky; Murray B Stein; Peter P Roy-Byrne Journal: Gen Hosp Psychiatry Date: 2007 Sep-Oct Impact factor: 3.238
Authors: Amy M Bauer; Vanessa Azzone; Laurie Alexander; Howard H Goldman; Jürgen Unützer; Richard G Frank Journal: Gen Hosp Psychiatry Date: 2011-10-21 Impact factor: 3.238
Authors: Michelle G Craske; Peter P Roy-Byrne; Murray B Stein; Greer Sullivan; Cathy Sherbourne; Alexander Bystritsky Journal: Behav Res Ther Date: 2009-07-14
Authors: Kate Wolitzky-Taylor; Jennifer Krull; Richard Rawson; Peter Roy-Byrne; Richard Ries; Michelle G Craske Journal: J Consult Clin Psychol Date: 2018-01
Authors: Amy M Bauer; Vanessa Azzone; Howard H Goldman; Laurie Alexander; Jürgen Unützer; Brenda Coleman-Beattie; Richard G Frank Journal: Psychiatr Serv Date: 2011-09 Impact factor: 3.084
Authors: R Kathryn McHugh; Victoria R Votaw; Olivera Bogunovic; Sterling L Karakula; Margaret L Griffin; Roger D Weiss Journal: Addict Behav Date: 2016-08-18 Impact factor: 3.913
Authors: Lily A Brown; Michelle G Craske; Daniel E Glenn; Murray B Stein; Greer Sullivan; Cathy Sherbourne; Alexander Bystritsky; Stacy S Welch; Laura Campbell-Sills; Ariel Lang; Peter Roy-Byrne; Raphael D Rose Journal: Depress Anxiety Date: 2012-12-05 Impact factor: 6.505
Authors: Julie Loebach Wetherell; Andrew J Petkus; Steven R Thorp; Murray B Stein; Denise A Chavira; Laura Campbell-Sills; Michelle G Craske; Cathy Sherbourne; Alexander Bystritsky; Greer Sullivan; Peter Roy-Byrne Journal: Br J Psychiatry Date: 2013-04-11 Impact factor: 9.319
Authors: Clair Cassiello-Robbins; Shannon Sauer-Zavala; Julianne G Wilner; Kate H Bentley; Laren R Conklin; Todd J Farchione; David H Barlow Journal: J Nerv Ment Dis Date: 2018-07 Impact factor: 2.254